CML drugs may secretly alter metabolism – study to investigate

NCT ID NCT07413263

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow 75 people with chronic myeloid leukemia who are taking tyrosine kinase inhibitors (imatinib or nilotinib). Researchers want to see if these drugs change blood sugar (HbA1c) and cholesterol levels. The goal is to understand side effects better, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Tyrosine kinase inhibitors (imatinib and nilotinib)

What this could lead to

If successful, this could help doctors better manage the side effects of CML drugs on metabolism.

What could go wrong

This is an observational study, not a treatment trial. It may not lead to any new therapies or changes in care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact